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MicroRNAs (miRNAs) are a class of recently identified noncoding RNAs that regulate gene expression at posttranscriptional level.
Due to the large number of genes regulated by miRNAs, miRNAs play important roles in many cellular processes. Emerging
evidenceindicatesthatmiRNAsaredysregulatedinpituitaryadenomas,aclassofintracranialneoplasmswhichaccountfor10–15%
ofdiagnosedbraintumors.DeregulatedmiRNAsandtheirtargetscontributetopituitaryadenomasprogressionandareassociated
with cell cycle control, apoptosis, invasion, and pharmacological treatment of pituitary adenomas. To provide an overview of
miRNAs dysregulation and functions of these miRNAs in pituitary adenoma progression, we summarize the deregulated miRNAs
and their targets to shed more light on their potential as therapeutic targets and novel biomarkers.
1. MicroRNAs
MicroRNAs (miRNAs) are a class of recently identified
noncoding RNAs. Mature miRNAs are short single-stranded
RNA molecules, approximately 19–23 nucleotides in length.
The miRNA sequence is encoded in a stem-loop structure
in the primary transcript that is cleaved in the nucleus by
the ribonuclease III enzyme Drosha to form the precur-
sor miRNA (pre-miRNA). The pre-miRNA is subsequently
exportedtothecytoplasmbytheexportinandtheniscleaved
by another ribonuclease III enzyme Dicer to form mature
miRNA [1–3]. Mature miRNAs can regulate the expres-
sion of a large number of genes at the posttranscriptional
level. miRNA is partially complementary to the sequence of
miRNA recognition elements (MRE) in the 3
򸀠 untranslated
regions (UTRs) of target mRNAs. The seed sequence with
seven nucleotides in miRNA determines the specificity of
mRNA targeting, whereas the remaining miRNA sequence
is supposed to stabilize the miRNA-target complex [4].
miRNA can inhibit translation of target mRNAs by blocking
protein translation machinery or by sequestering the mRNA
transcript away from ribosomal interaction. miRNA can
also induce target mRNA degradation in a similar way like
RNA interference [1, 5]. miRNAs have been identified in
a wide range of species, and computational analysis shows
that nearly 30% of protein-coding genes can be modulated
Hindawi Publishing Corporation
International Journal of Endocrinology
Volume 2014, Article ID 435171, 11 pages
http://dx.doi.org/10.1155/2014/4351712 International Journal of Endocrinology
by miRNAs [6]. In general, miRNAs negatively regulate the
expression of their targets. However, it is also reported that
miR-369-3pcanupregulatetheexpressionofitstarget,tumor
necrosis factor-𝗼 (TNF-𝗼)[ 7].
miRNAs have been demonstrated to play important
roles in many biological processes, such as cell cycle con-
trol, proliferation, apoptosis, differentiation, metabolism,
hemopoiesis, and development [8]. A rapidly growing body
of evidence shows that miRNAs also have comprehensive
functionsintumorprogression.SomemiRNAsmayfunction
as oncogenes (also called oncomirs) while some miRNAs
a r es u p p o s e dt ob et u m o rs u p p r e s s o r s[ 9]. The importance
of miRNAs in cancer is highlighted by the fact that half of
all miRNA genes are located in cancer-associated regions or
fragile sites, which are frequently altered or deleted in cancer
[10].ManytumortypesshowuniquemiRNAsignatures;thus,
miRNAs may be of use in cancer diagnosis and prognosis
[11, 12].
2. Pituitary Adenomas
Pituitary adenomas are usually benign intracranial neo-
p l a s m s ,a c c o u n t i n gf o r1 0 – 1 5 %o fd i a g n o s e db r a i nt u m o r s
[13]. Pituitary adenomas can be derived from a single
mutant cell of five differentiated cell types within pituitary
gland: somatotropes, lactotropes, corticotropes, thyrotropes,
and gonadotropes, which, respectively, secrete growth hor-
mone (GH), prolactin (PRL), adrenocorticotrophic hor-
mone (ACTH), thyroid-stimulating hormone (TSH), and
gonadotropins (follicle-stimulating hormone (FSH) and
luteinizing hormone (LH)). According to the hormonal
activity, pituitary adenomas can be defined as “functioning,”
causing endocrine dysfunction such as Cushing’s disease
in ACTH-secreting pituitary adenomas, acromegaly in GH-
secreting pituitary adenomas, galactorrhea and amenorrhea
in PRL-secreting pituitary adenomas, and hyperthyroidism
in TSH-secreting pituitary adenomas. On the other hand,
nonfunctioning pituitary adenomas (NFA) do not give rise
to hormone hypersecretion [14].
Pituitary adenomas might be small lesions with slow
growth. However, some pituitary adenomas grow rapidly
and cause tumor mass effect, the local compressive effect
of large pituitary tumors on brain structures and cranial
nerves. They can also invade downwards into the paranasal
sinuses, laterally into the cavernous sinuses and upwards
into the parenchyma of the brain. Occasionally, malignant
pituitary carcinomas metastasize to distant locations in the
central nervous system, lymph nodes, liver, and other sites
throughout the body [13].
In recent years, some reports demonstrated that pituitary
adenomashavealteredexpressionfilesofmiRNAs.Neverthe-
less, the correlation and function of miRNAs and their target
genes in pathogenesis of pituitary adenomas remain largely
unknown. Only a small number of miRNAs with their target
genes in pituitary adenomas have been validated so far. In
this review, we summarize recent advances in the study of
miRNAs and their validated or potential targets in pituitary
adenomas and discuss the future perspectives.
3. MicroRNAs in Pituitary Adenomas
3.1. Altered miRNA Expression in Pituitary Adenomas. Aber-
rant expressions of miRNAs have been demonstrated so far
(Table 1). miR-15a and miR-16-1 are the first two miRNAs
shown to have differential expression in pituitary adenomas.
miR-15a and miR-16-1 genes are located at chromosome
13q14,aregionwhichisfrequentlydeletedinpituitarytumors
[24]. Previous studies have suggested that the genes in this
locus may be responsible for the progression of pituitary
adenoma to a more aggressive form [25]. In 2005, miR-15a
and miR-16-1 were reported to have lower expression in both
GH-secreting and PRL-secreting pituitary adenomas than in
normaltissues,andtheirdownregulationwascorrelatedwith
greatertumorvolumeandimpairedsecretionofp43,apotent
anticancer cytokine, suggesting that miR-15a and miR-16-1
may function as tumor suppressors and their inactivation
may contribute to tumor growth in pituitary adenomas
[26]. In another study on ACTH-secreting pituitary tumors,
miR-15a and miR-16 were also expressed at a lower level
[27], but no association between miRNAs expression and
tumor size was observed in this study. This is in accordance
with the result of a subsequent report which showed no
correlation between downregulation of miR-15a and GH-
secreting pituitary tumor size [28]. Mutations in miR-16-1
gene have been reported to be partially responsible for its
altered expression in chronic lymphocytic leukemia (CLL)
patients [29]. Thus, it is worth exploring whether there are
similar mutations in pituitary adenoma patients.
let-7isoneofthefirstmembersinthemiRNAfamily.let-
7 family members are located at chromosomal regions that
are often altered or deleted in human tumors [10]. Down-
regulation of let-7 has been reported in breast, lung, colon,
and others cancers [30–33] and let-7 is considered a tumor
suppressor by targeting RAS oncogene [34]. Recently, some
studies revealed that high-mobility group A2 (HMGA2) is
negatively regulated by the let-7 miRNAs in vitro [35, 36].
HMGA2playsdiverserolesinmanybiologicalprocessessuch
asembryogenesis,differentiation,andneoplastictransforma-
tion[37].OverexpressionofHMGA2isahallmarkofvarious
tumors, including pituitary adenomas, and is associated with
highly malignancy [38, 39]. The transgenic mice with over-
expressedHMGA2developedpituitaryadenomas,indicating
that HMGA2 may be involved in pituitary tumorigenesis
[40]. In 2009, Qian et al. reported the clinical significance of
HMGA2overexpressioninpituitaryadenomas[15].HMGA2
was frequently upregulated in pituitary adenomas including
PRL, ACTH, FSH/LH, or null cell adenomas but relatively
rare in GH and mixed GH/PRL adenomas. The authors also
reporteddecreasedexpressionoflet-7inpituitaryadenomas.
Intriguingly,aninversecorrelationbetweenHMGA2andlet-
7 was confirmed in this study. HMGA2 overexpression and
t h ed e c r e a s eo fl e t - 7w e r es i g n i fi c a n t l yc o r r e l a t e dw i t ht u m o r
proliferation, growth, invasion, and tumor grade, which lead
to a hypothesis that let-7 may also function as a tumor
suppressor in pituitary adenomas by targeting HMGA2.
Decreased expression of let-7a in pituitary adenomas was
also reported in other studies [27, 41], suggesting the general
downregulation of let-7 in pituitary adenomas. On the otherInternational Journal of Endocrinology 3
Table 1: MicroRNAs and their target genes in human pituitary adenomas.
miRNA Upregulated or downregulated Target genes Tumor type Reference
let-7 Downregulated HMGA2 PRL, ACTH
FSH/LH
[15]
miR-23b Downregulated HMGA2 GH, NFA
FSH/LH
[16]
miR-26a Upregulated PRKCD ACTH [17]
miR-26b Upregulated PTEN GH [18]
miR-34b Downregulated HMGA1, HMGA2 GH [19]
miR-107 Upregulated AIP GH, NFA [20]
miR-128 Downregulated BMI1 GH [18]
miR-128a Upregulated Wee1 NFA [21]
miR-130b Downregulated CCNA2 GH, NFA
FSH/LH
[16]
miR-140-5p Upregulated Smad3 NFA [22]
miR-155 Upregulated Wee1 NFA [21]
miR-200c Upregulated PTEN PRL [23]
miR-326 Downregulated HMGA2, E2F1 GH [19]
miR-432 Downregulated HMGA2 GH [19]
miR-516a-3p Upregulated Wee1 NFA [21]
miR-548c-3p Downregulated HMGA1, HMGA2 GH [19]
miR-570 Downregulated HMGA2 GH [19]
miR-603 Downregulated E2F1 GH [19]
hand, some other miRNAs such as miR-98 can also regulate
HMGA2 expression [42], indicating that HMGA2 may have
multiple miRNAs regulators. During pituitary development,
let-7b/c was proposed to operate with the RNA-binding
protein KSRP in a negative feedback loop, in which KSRP
induces the maturation of let-7b/c, and let-7b/c posttran-
scriptionally downregulates the expression of KSRP itself
[43].
As pituitary adenomas can be derived from differenti-
ated cell types within pituitary gland, different subtypes of
pituitary adenomas could display distinct miRNA profiles,
and these specific profiles might be useful to distinguish
pituitary adenoma subtypes. In 2007, a list of thirty miRNAs
differentially expressed in pituitary adenomas was generated
by microarray [41]. Seven miRNAs were upregulated and
twenty-three were downregulated. The most representative
ones were miR-212, miR-026a, miR-150, miR-152, miR-191,
a n dm i R - 1 9 2 ,w h i c hw e r eu p r e g u l a t e di np i t u i t a rya d e n o m a s ,
w h i l em i R - 0 2 4 - 1a n dm i R - 0 9 8w e r ed o w n r e g u l a t e di nt u m o r
samples. Twenty-nine miRNAs were identified to be able
to predict pituitary adenoma histotype (ACTH-, GH-, PRL-
secreting adenomas, and NFA). For the limit of sample num-
bers, the authors only analyzed the association of deregulated
miRNAsandtumordiameterintheNFAgroup.FivemiRNAs
wereupregulated(miR-140,miR-099a,miR-099b,miR-030b,
and miR-030c) and only one (miR-138-2) was downregulated
in macroadenomas compared to microadenomas.
In 2009, Amaral et al. investigated the differential expres-
sion of some miRNAs in ACTH-secreting pituitary tumors.
In addition to the decrease of let-7a, miR-15a, and miR-
16, they also found underexpression of miR-21, miR-141,
miR-143, miR-145, and miR-150 in ACTH-secreting pituitary
adenomas compared with normal pituitary tissues [27].
Among these miRNAs, downregulation of miR-141 has been
reported in gastric cancer [44] and renal cell carcinoma
[45]. miR-143 expression was decreased in human lung
and colorectal cancers [46, 47]a n dw a sr e p o r t e dt oi n h i b i t
KRAS translation in colorectal cancer cell [48]. miR-145 was
downregulated in human breast, lung, and colorectal cancers
[30, 46, 47, 49]. miR-145 could regulate the expression of
various targets in different tumors: FSCN1 in esophageal
squamous cell carcinoma [50], OCT4, EGFR, and NUDT1
in lung adenocarcinoma [51, 52], and FLI1 in colon cancer
[53]. miR-143/145 cluster is a target of Jagged-1/Notch sig-
naling in vascular smooth muscle cells [54]. miR-150 was
overexpressed in hematopoietic progenitor/stem cells [55]
and was demonstrated to target NOTCH3 in human T-cell
development in a recent study [56].
Studies were conducted with the aim of investigating the
aberrant expression of miRNAs in GH-secreting pituitary
adenomas.In2010,Maoetal.identifiedtotallyfifty-twomiR-
NAs to be differentially expressed in GH-secreting pituitary
adenomas. Nine of these miRNAs had altered expression
between macro- and microadenomas. miR-184, miR-524-
5p, miR-629, and miR-766 were upregulated, while miR-
124, miR-222, miR-32, miR-744, and miR-765 were down-
regulated [28]. In 2012, another set of miRNAs were identi-
fied to be differentially expressed in GH-secreting pituitary
adenomas [19]. Eighteen miRNAs, including miR-34b, miR-
326, miR-432, miR-548c-3p, miR-570, and miR-603, were
drastically and constantly downregulated in GH adenomas,4 International Journal of Endocrinology
whereas only miR-320 was significantly upregulated. miR-
34b and miR-548c-3p were demonstrated to regulate both
HMGA1 and HMGA2 expression, whereas miR-326, miR-
432,andmiR-570targetHMGA2only.miR-326andmiR-603
could decrease the expression of the E2 transcription factor
1, E2F1. Besides, miR-107 was found to be overexpressed in
GH-secreting and nonfunctioning pituitary adenomas and
inhibited the expression of pituitary tumor suppressor gene
aryl hydrocarbon receptor-interacting protein (AIP) [20].
Recently, Palumbo et al. identified 17 miRNAs which were
differentially expressed in GH-secreting pituitary tumors.
Specifically, five miRNAs (miR-26b, miR-26a, miR-212, miR-
107, and miR-103) were upregulated and twelve miRNAs
(miR-125b, miR-141, miR-144, miR-164, miR-145, miR-143,
miR-15b, miR-16, miR-186, let-7b, let-7a3, and miR-128) were
downregulated. miR-26b and miR-128 controlled pituitary
cell properties through regulation of their direct targets,
PTEN, and BMI1, respectively [18]. miR-26b also targeted
Lef-1 and increased Pit-1 expression in GH3 cells [57].
m i R N A sa r ea l s od y s r e g u l a t e di nn o n f u n c t i o n i n gp i t u -
itary adenomas (NFA). In 2011, Butz et al. analyzed miRNAs
expression in NFA and the signaling pathways altered in
these pituitary tumors [22]. Expressions of Smad3, Smad6,
Smad9,MEG,andDLK1weresignificantlydecreasedinNFA.
Through pathway analysis and in silico target prediction, a
specificsubsetofmiRNAswasidentifiedthatmaypotentially
downregulate TGF-𝗽 signaling pathway in NFA. Five miR-
NAs predicted to target Smad3 (miR-135a, miR-140-5p, miR-
582-3p, miR-582-5p, and miR-938) were overexpressed, of
whichmiR-140-5phasalreadybeenvalidatedtotargetSmad3
directly [58]. In addition, an inverse correlation between
tumor size and the expression of eighteen miRNAs was
observed.SixmiRNAsofthem(miR-450b-5p,miR-424,miR-
503, miR-542-3p, miR-629, and miR-214) were significantly
underexpressed, while one miRNA (miR-592) was signifi-
cantly overexpressed in NFA compared to normal pituitary
tissues. In another study, miR-124a was the most upregulated
miRNA, and miR-31 was the most downregulated miRNA in
nonfunctioning pituitary adenomas [59].
In gonadotropin-secreting pituitary adenomas, a study
demonstrated that miR-10b was upregulated and miR-
503 was downregulated [59]. Furthermore, the integra-
tion and coordination of hormones and pituitary cells are
important for the regulatory function of pituitary tissues.
Gonadotropin-Releasing Hormone (GnRH) acts on pitu-
itary gonadotropes to stimulate LH and FSH synthesis and
secretion. GnRH induces expressions of miR-132 and miR-
212 in L𝗽T2 pituitary gonadotrope cells to regulate cellular
morphology and migration. The p250RhoGAP protein is a
downstream target of miR132/212 and its downregulation is
involved in the morphological change and migration altered
by GnRH [60].
3.2. Functional Association of miRNAs in
Pituitary Tumorigenesis and Progression
3.2.1. miRNAs and Cell Cycle in Pituitary Adenomas. It is
w e l lk n o w nt h a tt h ed y s f u n c t i o no fc e l lc y c l ec o n t r o li s
acriticalstepininitiationandprogressionofhumancancers.
Some oncoproteins or tumor suppressors play important
rolesincellcyclecontrolbyinteractingwithcriticalcellcycle
regulators, such as cyclin, cyclin-dependent-kinase (CDK),
or cell cycle inhibitors. During tumor progression, the genes
involved in cell cycle control often have aberrant expression,
resulting in unlimited tumor cell growth [61]. Some reports
suggested that the deregulated miRNAs might also regulate
cell cycle of pituitary adenomas at the post-transcriptional
level (Figure 1).
Wee1 was described as a tumor suppressor to inhibit cell
cycle. Wee1 phosphorylates Cdk1 and inhibits its activity to
block cell cycle in G2/M checkpoint [62]. Wee1 was down-
regulated in GH-secreting and NFA pituitary adenomas.
miR-128a, miR-155, and miR-516a-3p target 3
򸀠-UTR of Wee1,
and exogenous overexpression of these miRNAs inhibited
Wee1 expression [21]. miR-128a is a brain-enriched miRNA
and was reported to be decreased in pituitary adenomas
[41]. Its ectopic overexpression reduced neuroblastoma cell
motility and invasiveness [63], suggesting its tumor sup-
pressive role. miR-155 was reported as an oncomir in both
hemopoietic malignancies and solid tumors [64]. miR-516a-
3p was involved in glioblastoma development [65]a n dw a s
associated with progression of breast cancer [66]. These
miRNAs may take part in the regulation of cell cycle in
pituitary adenomas together with other related miRNAs.
HMGA2 is associated with the E1A-regulated transcrip-
tional repressor p120 (E4F), interfering with p120 (E4F)
binding to the cyclin A promoter. Ectopic expression of
HMGA2 resulted in the activation of cyclin A promoter
and induction of endogenous cyclin A expression. Moreover,
chromatin immunoprecipitation experiments showed that
HMGA2 was associated with cyclin A promoter only when
the gene was transcriptionally activated. These data indicate
cyclin A as a cellular target of HMGA2 and, for the first
time, lead to a mechanism of HMGA2-dependent cell cycle
regulation [67]. Thus, let-7, as a regulator of HMGA2, may
exert its effects in cell cycle control of pituitary adenomas
by targeting HMGA2. miR-23b and miR-130b, which were
reduced in GH, gonadotroph, and NFPA adenomas, were
demonstrated to target HMGA2 and cyclin A2, respectively.
Overexpression of miR-23b and miR-130b arrested the cells
in the G1 and G2 phase of the cell cycle [16].
Recently, a study revealed that miR-15a and miR-16-1
cluster could modulate prostate cancer by targeting multiple
genes, including cyclin D1 [68]. Regarding the deregulation
in pituitary adenomas, miR-15a and miR-16-1 may exert their
rolesastumorsuppressorsbyregulatingcellcycle.Expression
of miR-126 and miR-381 was decreased in GH-secreting
pituitary adenomas [28]. Previous study has shown that mir-
126 could modulate phosphatidylinositol 3-kinase (PI3K)
signalingbylimitingthePI3Kregulatorysubunitbeta(p85b).
LossofmiR-126wouldeliminatethecheckpointandincrease
PI3K signaling, which facilitate tumor growth during colon
carcinogenesis [69] .m i R - 1 4 5w a sd o w n r e g u l a t e di nG H -
secreting pituitary adenomas [28], which is in line with the
results in 11 samples of cortitropinomas [27]. The potential
targets of miR-145 include myc, kras, fos, yes, fli, cyclin D2,International Journal of Endocrinology 5
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Figure 1: Functions of miRNAs as oncogenic and tumor suppressive genes in pituitary adenomas. (a) Upregulation of oncogenic miRNAs
(oncomiRs) in pituitary adenomas results in suppression of their target tumor suppressor genes (e.g., TP53, MEN1, and RB1). (b)
Downregulation of tumor suppressive miRNAs results in upregulation of their target oncogenes (e.g., Gsp, Ras, and Cyclin D1). The
consequence of oncomiRs and tumor suppressive miRNAs regulation in pituitary adenomas might involve aberrant proliferation, cell cycle
control, apoptosis, and invasiveness.
and MAPK transduction proteins [30], indicating that miR-
145 might function in cell cycle control by targeting multiple
genes. miR-503 was highly expressed in NFA and had a
negative correlation with tumor size [22]. miR-503 has been
v a l i d a t e dt od i r e c t l yt a r g e tc y c l i nD 1a n di st h o u g h tt ob ea
tumor suppressor [70]. Furthermore, an important potential
target of miR-503 is the cell cycle regulator CDC25.
miR-26b and miR-128 were found to directly regulate
PTEN and BMI1, respectively. Moreover, miR-128 regulated
PTENexp r essionandAk tactivityinthep ituitarytumorcells
by interfering with the binding of BMI1 to PTEN promoter
[18]. Since PTEN-Akt pathway plays important roles in cell
cycle control, miR-26b and miR-128 might regulate cell cycle
through PTEN-Akt pathway [71]. Moreover, miR-26a was
also overexpressed in ACTH-secreting pituitary adenomas
and plays an important role in cell cycle control by modu-
l a t i n gp r o t e i nk i n a s eCd e l t a[ 17].
3.2.2. miRNAs and Apoptosis in Pituitary Adenomas. Apop-
tosis, the process of programmed cell death, is an important6 International Journal of Endocrinology
barrierfortumorcells.Duringmalignanttransformationand
tumor progression, tumor cells have to escape this regulated
cell death to obtain an advantage in growth and expansion.
At the early stage of apoptosis,cells receive death signals,and
thenthe“apoptotictrigger”iscontrolledbypro-orantiapop-
totic members of B-cell lymphoma 2 (Bcl-2) family and other
regulatory proteins [72]. Accumulating evidence have shown
that miRNAs can regulate cancer cell apoptosis by targeting
Bcl-2 family or other apoptosis regulators (Figure 1).
miR-15a and miR-16-1 were demonstrated to induce
apoptosis by targeting Bcl-2 in CLL [73]. Bcl-2 is a founding
memberoftheBcl-2family,afamilyofantiapoptoticproteins
governing mitochondrial death signaling. Bcl-2 is frequently
overexpressed in many types of human cancers, including
carcinomas, lymphomas, and leukemias [74]. In CLL, some
other apoptosis related genes were identified to be targets of
miR-15a and miR-16-1 cluster, such as MCL1, which could
enhance cell survival by inhibiting apoptosis. Therefore, it is
possible that, in pituitary adenomas, miR-15a and miR-16-1
influenceapoptosisbytargetingmultipleantiapoptoticgenes.
Besides, miR-214 and miR-629, two miRNAs overexpressed
in NFA and negatively correlated with tumor size, also
potentially target Bcl2 [22].
miR-21 was differentially expressed in ACTH-secreting
pituitary adenomas compared with normal pituitary tissues
[27]. miR-21 has been identified to be upregulated in human
breast,lung,colorectalandothercancers[30,46,49,75].Sup-
pression of miR-21 by antisense oligonucleotides or miR-21
knockdown was associated with increased apoptotic activity
and inhibition of tumor cell growth, probably by downreg-
ulating the target tumor suppressor genes [76]. miR-21 may
exert its function in apoptosis by targeting tumor suppressor
Pdcd4 [77]a n dP T E N[ 78]. Overexpression of PDCD4 was
able to result in apoptotic death [79] ,a n dP T E Nc a ni n d u c e
apoptosis through phosphoinositol-3-kinase/Akt dependent
and independent pathways [80]. miR-21 is upregulated both
in vitro and in vivo by oncogenic Ras [81].
miR-212 is strongly upregulated in pituitary adenomas
[41]. Putative targets of miR-212 include death effector
domain-containing protein (DEDD), a protein involved in
apoptotic signaling [82], as well as other proteins participat-
i n gi na p o p t o s i s .m i R 1 8 4w a sm a r k e d l yu p r e g u l a t e di nG H -
secreting pituitary adenomas and was correlated with tumor
diameter [28]. Contrary to that, another study reported
that ectopic overexpression of miR-184 resulted in increased
apoptosis [83]. Study of Cheng et al. suggested that the
upregulated miR-150, miR-152, miR-191, and miR-192 may
also be involved in apoptosis [84].
miR-26b was found to be upregulated in GH-secreting
pituitarytumorsanddirectlyregulatePTEN.Therefore,miR-
2 6 bi sa b l et or e g ula t ea po p t o s i sth r o u ghP T E N - Ak tpa th w a y .
miR-200c, which has been characterized as a tumor suppres-
sor or oncogene in different cancers, also inhibited apop-
tosis in pituitary adenoma cells by targeting the PTEN/Akt
signaling pathway [23]. Intriguingly, a novel marine drug,
SZ-685C that was isolated from the secondary metabolites
of a mangrove endophytic fungus was reported to induce
apoptosis of MMQ pituitary tumor cells by downregulating
miR-200c [85].
TGF-𝗽 has been shown to inhibit proliferation and
induce apoptosis in HP75 cells, a cell line derived from a
clinically NFA [86]. Thereby, the miRNAs targeting TGF-𝗽
signaling (miR-135a, miR-140-5p, miR-582-3p, miR-582-5p,
and miR-938) may have effects in apoptosis [22]. However,
as TGF-𝗽 can also promote cancer cell invasion by inducing
Epithelial-Mesenchymal Transition (EMT) [87], it is rational
to conclude that miRNAs targeting TGF-𝗽 pathway may
suppress invasion and metastasis by blocking EMT, as miR-
300doesinhumanepithelialcancer[88].Therefore,miRNAs
that regulate TGF-𝗽 pathway play controversial roles in
tumor initiation and progression. Deregulation of BMI1 has
been revealed to affect apoptosis; thus, miR-128, which was
downregulated in GH-secreting pituitary tumors, could also
affect apoptosis by directly regulating BMI1 [18]. These data
together lead to the hypothesis that many miRNAs may
function in a network to regulate apoptosis in pituitary
adenomas.
3.2.3. miRNAs and Invasion or Metastasis of Pituitary Ade-
nomas. Invasion and metastasis are critical lethal factors
for malignant cancer. Although invasion and metastasis
a r er a r ei np i t u i t a r yt u m o r s ,s t u d i e sp r o v i d es o m ec l u e so f
miRNAs’functioninpituitarytumorinvasionandmetastasis
(Figure 1).
Significant correlation between HMGA2 overexpression
and tumor cell invasion has been detected in breast cancer
and gastric cancer [89, 90]. In oral squamous cell carci-
nomas, strong staining of HMGA2 and loss of E-cadherin
expression were observed at the invasive front of tumor
[91]. Previous studies also demonstrated that tumor-specific
downregulation of E-cadherin and H-cadherin was related
to invasiveness of pituitary adenoma [92]. HMGA2 may
be involved in tumor cell invasion due to its association
with epithelial-mesenchymal transition that facilitates tumor
cell invasion. Since let-7 regulates HMGA2 expression in
pituitary adenomas, let-7 may also take a role in pituitary
adenoma invasion. In Amaral et al.’s study, although no
association between miRNAs expression and tumor size was
observed,thepatientswithACTH-secretingpituitarytumors
expressing reduced miR-141 had more chance of remission
after transsphenoidal surgery, suggesting that miR-141 may
regulate pituitary genes involved in tumor growth and local
invasion [27] .P T T Gp r o t e i n1i sat a r g e to fb o t hm i R - 1 2 6
and miR-381, which were downregulated in GH-secreting
pituitary adenomas [28]. PTTG is overexpressed in most
pituitary adenomas and is involved in tumor invasion [93].
Therefore, miR-126 and miR-381 might regulate pituitary
adenoma invasion by targeting PTTG.
Aggressive pituitary adenomas and carcinomas fre-
quently have a deletion in regions near the RB gene [94, 95].
In 2010, Stilling et al. investigated the expression of miRNAs
in pituitary carcinomas [96]. In one case, ACTH carcinoma
had metastatic carcinomas in three sites. More miRNAs
were deregulated between pituitary adenomas and normal
pituitaries compared to carcinomas and normal pituitaries.
In pituitary carcinomas compared to ACTH adenomas, miR-
122andmiR-493wereupregulated,and,inallthreemetastaticInternational Journal of Endocrinology 7
sitesofACTHcarcinomas,miR-122expressionwasmarkedly
increased.
Recently,Palumboetal.identifiedmiR-26btobeupregu-
latedandmiR -128tobedownregulatedinGH-secretingpitu-
itary tumors [18]. Inhibition of miR-26b and overexpression
of miR-128 suppressed colony formation and invasiveness of
pituitary tumor cells. Interestingly, the inhibition of miR-26b
a n do v e r e x p r e s s i o no fm i R - 1 2 8h a das y n e r g i s t i ce ff e c to n
suppressing the tumorigenicity and invasiveness of pituitary
tumors. Since deregulation of PTEN and BMI1 correlates
withtheinvasiveandmetastaticphenotypeofseveralhuman
cancer types [97, 98], it is possible that miR-26b and miR-
128 regulate invasiveness of pituitary tumor cells by directly
targeting PTEN and BMI1, respectively. Although metastatic
pituitary carcinomas are rare, these data suggest that altered
expressionofmiRNAsmayprovidediagnosticinformationto
distinguish pituitary adenomas and carcinomas before they
metastasize.
3.2.4. miRNAs and Pharmacological Treatment of Pituitary
Adenomas. The symptoms of mass effect and hormonal
hypersecretion caused by pituitary adenomas could be
reversed by surgical resection or debulking of the adenoma,
radiotherapy, or medical treatment. Medical treatment is the
primary choice for prolactinomas and the secondary option
for acromegaly, Cushing’s disease, gonadotropin-secreting
tumours, and TSH-secreting adenomas [99]. Some studies
provide evidence that miRNAs were differentially expressed
before and after pharmacological treatment, and the altered
miRNA profile could provide useful information of respon-
siveness of pituitary adenomas patients to pharmacological
treatment (Figure 1).
In 2007, a microarray was carried out to analyze the
miRNA profiles in pituitary adenomas and normal pituitary
samples. To elucidate whether miRNAs profile is altered by
pharmacological treatment, differentially expressed miRNAs
were identified in NFA from patients with pharmacological
treatment or patients without treatment [41]. Six miRNAs
were found to be differentially expressed: miR-29b, miR-
29c, and miR-200a were upregulated, while miR-134, miR-
148,andmiR-155weredownregulatedaftertreatment.Cluster
analysis showed clear distinction between pharmacological
treated and nontreated NFA. Thus, the miRNA expression
could differentiate treated patient samples from nontreated
patient samples.
In 2010, another study aimed to identify altered expres-
sion of miRNAs in GH-secreting pituitary adenomas [28].
Fifteen pituitary adenomas patients were treated with lan-
reotide for four months before surgery, while six patients did
not receive any presurgical medical treatments. Patients with
>50% reduction of GH secretion after lanreotide treatment
were considered somatostatin analogs (SSA) responders,
while patients with <50% GH secretion were considered
SSA nonresponders [100]. Thirteen miRNAs were differen-
tially expressed between GH-secreting pituitary adenomas
from patients with lanreotide treatment and those without
treatment. Eight miRNAs (miR-183, miR-193a-5p, miR-222,
miR-516b, miR-524-5p, miR-601, and miR-629, 99b) were
upregulated and five miRNAs (miR-124, miR-32, miR-574-
5p, miR-744, and miR-96) were downregulated. Moreover,
seven miRNAs were differentially expressed between SSA
responders and SSA nonresponders. Putative targets of these
miRNAs are mainly IGFBP family members, IGFALS, SCP1,
and matrix metalloproteinase-9.
4. Conclusion and Future Perspectives
Accumulating evidence demonstrates that a large number of
miRNAs have altered expression in pituitary adenomas, and
thesemiRNAsmayplayimportantrolesintumorprogression
by targeting multiple genes. The molecular mechanism of
the regulation of miRNAs in pituitary adenomas is still a
mystery. Some proofs indicate that genetic or epigenetic
alterations may contribute to the deregulated expression of
miRNAs. For example, mutations in the miR-16-1 gene have
been reported to be partially responsible for its aberrant
expression in CLL patients [29], and expressions of miR-
124 and miR-203 are decreased because of CpG methylation
[101]. Some miRNAs have been demonstrated to target
multiple genes, indicating that they may have different roles
in pituitary tumors. On the other hand, a gene involved in
pituitary adenomas progression can be modulated by more
than one miRNA. Therefore, the miRNAs and their targets
could regulate pituitary adenomas progression in a complex
network.
Advances in the technology to investigate miRNAs make
it easier and faster to explore more exactly the roles of
miRNAs in pituitary adenomas. As some miRNAs signatures
c a nb eu s e dt od i s t i n g u i s hp i t u i t a r ya d e n o m a sa n dn o r m a l
pituitaries and even subtypes of pituitary tumors, it is also
possible to develop miRNA based diagnosis and therapies of
pituitary adenomas. The knowledge of pituitarypathogenesis
isstilllimited.ContinuingstudyonmiRNAsandtheirtargets
will shed more light on mechanisms of pituitary adenomas.
Conflict of Interests
The authors declare that there is no conflict of interests
regarding the publication of this paper.
Authors’ Contribution
Xu-Hui Li and Zhi Rong Qian contributed equally to this
work.
Acknowledgments
This work was supported by the Natural Science Foundation
of Zhejiang Province (no. LY14C060002); the fund from the
ScienceandTechnologyBureauofJiaxing(no.2014AY21022);
t h eO p e nF u n do fZ h e j i a n gP r o v i n c i a lT o pK e yD i s c i p l i n eo f
Biology; the fund from Science and Technology of Xiaoshan
District (no. 2012121); and the China Natural Science Foun-
dation (no. 31170732 and no. 31270854).8 International Journal of Endocrinology
References
[1] D. P. Bartel, “MicroRNAs: genomics, biogenesis, mechanism,
and function,” Cell,v o l .1 1 6 ,n o .2 ,p p .2 8 1 – 2 9 7 ,2 0 0 4 .
[2] Y. Lee, K. Jeon, J.-T. Lee, S. Kim, and V. N. Kim, “MicroRNA
maturation: stepwise processing and subcellular localization,”
The EMBO Journal,v o l .2 1 ,n o .1 7 ,p p .4 6 6 3 – 4 6 7 0 ,2 0 0 2 .
[3] R. Yi, Y. Qin, I. G. Macara, and B. R. Cullen, “Exportin-
5m e d i a t e st h en u c l e a re x p o r to fp r e - m i c r o R N A sa n ds h o r t
hairpinRNAs,”GenesandDevelopment,vol.17 ,no .2 4,p p .3011 –
3016, 2003.
[ 4 ]B .P .L e w i s ,C .B .B u r g e ,a n dD .P .B a r t e l ,“ C o n s e r v e ds e e d
pairing, often flanked by adenosines, indicates that thousands
of human genes are microRNA targets,” Cell,v o l .1 2 0 ,n o .1 ,p p .
15–20, 2005.
[5] B. Bartel, “MicroRNAs directing siRNA biogenesis,” Nature
Structural and Molecular Biology,v o l .1 2 ,n o .7 ,p p .5 6 9 – 5 7 1 ,
2005.
[6] W.Filipowicz,S.N.Bhattacharyya,andN.Sonenberg,“Mecha-
nismsofpost-transcriptionalregulationbymicroRNAs:arethe
answersinsight?”NatureReviewsGenetics,vol.9 ,no.2,pp.102–
114, 2008.
[7] S. Vasudevan, Y. Tong, and J. A. Steitz, “Switching from repres-
sion to activation: microRNAs can up-regulate translation,”
Science, vol. 318, no. 5858, pp. 1931–1934, 2007.
[8] V. Ambros, “The functions of animal microRNAs,” Nature,v o l .
431, no. 7006, pp. 350–355, 2004.
[ 9 ] A .L .G a r t e la n dE .S .K a n d e l ,“ m i R N A s :l i t t l ek n o w nm e d i a t o r s
of oncogenesis,” Seminars in Cancer Biology,v o l .1 8 ,n o .2 ,p p .
103–110, 2008.
[10] G. A. Calin, C. Sevignani, C. D. Dumitru et al., “Human
microRNA genes are frequently located at fragile sites and
genomic regions involved in cancers,” Proceedings of the
National Academy of Sciences of the United States of America,
vol. 101, no. 9, pp. 2999–3004, 2004.
[11] K. M. Nelson and G. J. Weiss, “MicroRNAs and cancer: past,
present, and potential future,” Molecular Cancer Therapeutics,
v o l .7 ,n o .1 2 ,p p .3 6 5 5 – 3 6 6 0 ,2 0 0 8 .
[12] J.-X. Zhang, W. Song, Z.-H. Chen et al., “Prognostic and
predictive value of a microRNA signature in stage II colon
cancer: a microRNA expression analysis,” The Lancet Oncology,
v o l .1 4 ,n o .1 3 ,p p .1 2 9 5 – 1 3 0 6 ,2 0 1 3 .
[ 1 3 ] S .L .A s aa n dS .E z z a t ,“ Th ep a t h o g e n e s i so fp i t u i t a ryt u m o u r s , ”
Nature Reviews Cancer,v o l .2 ,n o .1 1 ,p p .8 3 6 – 8 4 9 ,2 0 0 2 .
[14] S.EzzatandS.L.Asa,“Mechanismsofdisease:thepathogenesis
of pituitary tumors,” Nature Clinical Practice Endocrinology &
Metabolism,v o l .2 ,n o .4 ,p p .2 2 0 – 2 3 0 ,2 0 0 6 .
[15] Z. R. Qian, S. L. Asa, H. Siomi et al., “Overexpression of
HMGA2 relates to reduction of the let-7 and its relationship
to clinicopathological features in pituitary adenomas,” Modern
Pathology,v o l .2 2 ,n o .3 ,p p .4 3 1 – 4 4 1 ,2 0 0 9 .
[16] V. Leone, C. Langella, D. D’Angelo et al., “MiR-23b and
miR-130b expression is downregulated in pituitary adenomas,”
Molecular and Cellular Endocrinology,v o l .3 9 0 ,n o .1 - 2 ,p p .1 – 7 ,
2014.
[17] E.Gentilin,F.Tagliati,C.Filierietal.,“MiR-26aplaysanimpor-
tant role in cell cycle regulation in ACTH-secreting pituitary
adenomasbymodulatingproteinkinaseCdelta,”Endocrinology,
vol. 154, no. 5, pp. 1690–1700, 2013.
[18] T. Palumbo, F. R. Faucz, M. Azevedo, P. Xekouki, D. Iliopoulos,
and C. A. Stratakis, “Functional screen analysis reveals miR-
26b and miR-128as central regulators of pituitary somatomam-
motrophictumor growththroughactivation ofthePTEN-AKT
pathway,” Oncogene,v o l .3 2 ,n o .1 3 ,p p .1 6 5 1 – 1 6 5 9 ,2 0 1 3 .
[19] D.D’Angelo,D.Palmieri,P.Mussnichetal.,“AlteredmicroRNA
expression profile in human pituitary GH adenomas: down-
regulation of miRNA targeting HMGA1, HMGA2, and E2F1,”
Journal of Clinical Endocrinology and Metabolism,v o l .9 7 ,n o .7 ,
pp. E1128–E1138, 2012.
[20] G. Trivellin, H. Butz, J. Delhove et al., “MicroRNA miR-
107 is overexpressed in pituitary adenomas and inhibits the
expression of aryl hydrocarbon receptor-interacting protein in
vitro,” The American Journal of Physiology—Endocrinology and
Metabolism,v o l .3 0 3 ,n o .6 ,p p .E 7 0 8 – E 7 1 9 ,2 0 1 2 .
[21] H. Butz, I. Lik´ o, S. Czirj´ ak et al., “Down-regulation of Wee1
kinase by a specific subset of microRNA in human sporadic
pituitary adenomas,” The Journal of Clinical Endocrinology &
Metabolism,v o l .9 5 ,n o .1 0 ,p p .E 1 8 1 – E 1 9 1 ,2 0 1 0 .
[ 2 2 ]H .B u t z ,I .L i k ´ o, S. Czirj´ ak et al., “MicroRNA profile indi-
cates downregulation of the TGF𝗽 pathway in sporadic non-
functioning pituitary adenomas,” Pituitary,v o l .1 4 ,n o .2 ,p p .
112–124, 2011.
[ 2 3 ]C .L i a o ,W .C h e n ,X .F a ne ta l . ,“ M i c r o R N A - 2 0 0 ci n h i b i t s
apoptosisinpituitaryadenomacellsbytargetingthePTEN/Akt
signalingpathway,”OncologyResearch,vol.21,pp.129–136,2014.
[24] G. A. Calin, C. D. Dumitru, M. Shimizu et al., “Frequent
deletions and down-regulation of micro-RNA genes miR15 and
miR16at13q14inchroniclymphocyticleukemia,”Proceedingsof
theNationalAcademyofSciencesoftheUnitedStatesofAmerica,
v o l .9 9 ,n o .2 4 ,p p .1 5 5 2 4 – 1 5 5 2 9 ,2 0 0 2 .
[25] L.Pei,S.Melmed,B.Scheithauer,K.Kovacs,W.F.Benedict,and
D.Prager,“Frequentlossofheterozygosityattheretinoblastoma
susceptibility gene (RB) locus in aggressive pituitary tumors:
evidence for a chromosome 13 tumor suppressor gene other
than RB,” Cancer Research,v o l .5 5 ,n o .8 ,p p .1 6 1 3 – 1 6 1 6 ,1 9 9 5 .
[26] A. Bottoni, D. Piccin, F. Tagliati, A. Luchin, M. C. Zatelli, and
E. C. D. Uberti, “miR-15a and miR-16-1 down-regulation in
pituitary adenomas,” Journal of Cellular Physiology,vol.204,no .
1, pp. 280–285, 2005.
[27] F.C.Amaral,N.Torres,F.Saggioroetal.,“MicroRNAsdifferen-
tiallyexpressedinACTH-secretingpituitarytumors,”Journal of
Clinical Endocrinology and Metabolism,v o l .9 4 ,n o .1 ,p p .3 2 0 –
323, 2009.
[28] Z.-G. Mao, D.-S. He, J. Zhou et al., “Differential expression of
microRNAs in GH-secreting pituitary adenomas,” Diagnostic
Pathology,v o l .5 ,n o .1 ,a r t i c l e7 9 ,2 0 1 0 .
[29] G. A. Calin, M. Ferracin, A. Cimmino et al., “A microRNA
signature associated with prognosis and progression in chronic
lymphocytic leukemia,” The New England Journal of Medicine,
vol. 353, no. 17, pp. 1793–1801, 2005.
[30] M. V. Iorio, M. Ferracin, C.-G. Liu et al., “MicroRNA gene
expression deregulation in human breast cancer,” Cancer
Research, vol. 65, no. 16, pp. 7065–7070, 2005.
[31] J. Takamizawa, H. Konishi, K. Yanagisawa et al., “Reduced
expression of the let-7 microRNAs in human lung cancers
in association with shortened postoperative survival,” Cancer
Research, vol. 64, no. 11, pp. 3753–3756, 2004.
[32] Y. Akao, Y. Nakagawa, and T. Naoe, “let-7 microRNA functions
as a potential growth suppressor in human colon cancer cells,”
Biological&PharmaceuticalBulletin,vol.29 ,no .5,pp .903–906,
2006.International Journal of Endocrinology 9
[33] S. Shell, S.-M. Park, A. R. Radjabi et al., “Let-7 expression
defines two differentiation stages of cancer,” Proceedings of the
National Academy of Sciences of the United States of America,
v o l .1 0 4 ,n o .2 7 ,p p .1 1 4 0 0 – 1 1 4 0 5 ,2 0 0 7 .
[34] S.M.Johnson,H.Grosshans,J.Shingaraetal.,“RASisregulated
by the let-7 microRNA family,” Cell,v o l .1 2 0 ,n o .5 ,p p .6 3 5 – 64 7 ,
2005.
[ 3 5 ]C .M a y r ,M .T .H e m a n n ,a n dD .P .B a r t e l ,“ D i s r u p t i n gt h e
pairingbetweenlet-7andHmga2enhancesoncogenictransfor-
mation,” Science,v o l .3 1 5 ,n o .5 8 1 8 ,p p .1 5 7 6 – 1 5 7 9 ,2 0 0 7 .
[36] Y. S. Lee and A. Dutta, “The tumor suppressor microRNA let-7
repressestheHMGA2oncogene,”Genes&Development,vol.21,
no. 9, pp. 1025–1030, 2007.
[37] R. Sgarra, A. Rustighi, M. A. Tessari et al., “Nuclear phos-
phoproteins HMGA and their relationship with chromatin
structure and cancer,” FEBS Letters,v o l .5 7 4 ,n o .1 – 3 ,p p .1 – 8 ,
2004.
[38] A. Fusco and M. Fedele, “Roles of HMGA proteins in cancer,”
Nature Reviews Cancer, vol. 7, no. 12, pp. 899–910, 2007.
[39] P. Finelli, G. M. Pierantoni, D. Giardino et al., “The High
Mobility Group A2 gene is amplified and overexpressed in
human prolactinomas,” Cancer Research,v o l .6 2 ,n o .8 ,p p .
2398–2405, 2002.
[40] M. Fedele, S. Battista, L. Kenyon et al., “Overexpression of the
HMGA2 gene in transgenic mice leads to the onset of pituitary
adenomas,” Oncogene, vol. 21, no. 20, pp. 3190–3198, 2002.
[41] A. Bottoni, M. C. Zatelli, M. Ferrcin et al., “Identification of
differentially expressed microRNAs by microarray: a possible
role for microRNA genes in pituitary adenomas,” Journal of
Cellular Physiology,v o l .2 1 0 ,n o .2 ,p p .3 7 0 – 3 7 7 ,2 0 0 7 .
[ 42 ] C .H e be rt ,K .N o rri s ,M .A .Sc h e pe r ,N .N ik i ta k i s ,a n dJ .J .S a uk ,
“High mobility group A2 is a target for miRNA-98 in head and
necksquamouscellcarcinoma,”MolecularCancer,vol.6,article
5, 2007.
[43] E. Repetto, P. Briata, N. Kuziner et al., “Let-7b/c enhance
the stability of a tissue-specific mRNA during mammalian
organogenesis as part of a feedback loop involving KSRP,” PLoS
Genetics,v o l .8 ,n o .7 ,A r t i c l eI De 1 0 0 2 8 2 3 ,2 0 1 2 .
[44] Y. Du, Y. Xu, L. Ding et al., “Down-regulation of miR-141 in
gastric cancer and its involvement in cell growth,” Journal of
Gastroenterology,v o l .4 4 ,n o .6 ,p p .5 5 6 – 5 6 1 ,2 0 0 9 .
[45] C. Nakada, K. Matsuura, Y. Tsukamoto et al., “Genome-wide
microRNA expression profiling in renal cell carcinoma: signifi-
cant down-regulation of miR-141 and miR-200c,” The Journal of
Pathology,v o l .2 1 6 ,n o .4 ,p p .4 1 8 – 4 2 7 ,2 0 0 8 .
[46] N. Yanaihara, N. Caplen, E. Bowman et al., “Unique microRNA
molecular profiles in lung cancer diagnosis and prognosis,”
Cancer Cell,v o l .9 ,n o .3 ,p p .1 8 9 – 1 9 8 ,2 0 0 6 .
[47] M. Z. Michael, S. M. O’Connor, N. G. van Holst Pellekaan, G.
P. Young, and R. J. James, “Reduced accumulation of specific
microRNAsincolorectalneoplasia,”MolecularCancerResearch,
v o l .1 ,n o .1 2 ,p p .8 8 2 – 8 9 1 ,2 0 0 3 .
[48] X. Chen, X. Guo, H. Zhang et al., “Role of miR-143 targeting
KRASincolorectaltumorigenesis,”Oncogene,vol.28,no.10,pp.
1385–1392, 2009.
[49] E. Bandr´ es, E. Cubedo, X. Agirre et al., “Identification by real-
time PCR of 13 mature microRNAs differentially expressed in
colorectal cancer and non-tumoral tissues,” Molecular Cancer,
vol. 5, article 29, 2006.
[50] M. Kano, N. Seki, N. Kikkawa et al., “miR-145, miR-133a
and miR-133b: tumor-suppressive miRNAs target FSCN1 in
esophageal squamous cell carcinoma,” International Journal of
Cancer,v o l .1 2 7 ,n o .1 2 ,p p .2 8 0 4 – 2 8 1 4 ,2 0 1 0 .
[51] S. Zhang, Y. Wu, D. Feng et al., “miR-145 inhibits lung ade-
nocarcinoma stem cells proliferation by targeting OCT4 gene,”
Zhongguo Fei Ai Za Zhi,v o l .1 4 ,n o .4 ,p p .3 1 7 – 3 2 2 ,2 0 1 1 .
[52] W. C. S. Cho, A. S. C. Chow, and J. S. K. Au, “MiR-145 inhibits
cell proliferation of human lung adenocarcinoma by targeting
EGFRandNUDT1,”RNA Biology,v o l .8,n o .1,p p .125–13 1,20 11.
[53] J. Zhang, H. Guo, H. Zhang et al., “Putative tumor suppressor
miR-145inhibitscoloncancercellgrowthbytargetingoncogene
friend leukemia virus integration 1 gene,” Cancer,v o l .1 1 7 ,n o .1 ,
p p .8 6 – 9 5 ,2 0 1 1 .
[54] J.M.Boucher ,S.M.Peterson,S.Urs,C.Zhang,andL.Liaw ,“The
miR-143/145 cluster is a novel transcriptional target of Jagged-
1/Notch signaling in vascular smooth muscle cells,” The Journal
of Biological Chemistry,v o l .2 8 6 ,n o .3 2 ,p p .2 8 3 1 2 – 2 8 3 2 1 ,2 0 1 1 .
[ 5 5 ] B .Z h o u ,S .W a n g,C .M a y r ,D .P .Ba rt e l ,a n dH .F .Lod i s h ,“ m i R -
150,amicroRNAexpressedinmatureBandTcells,blocksearly
Bcelldevelopmentwhenexpressedprematurely,”Proceedingsof
theNationalAcademyofSciencesoftheUnitedStatesofAmerica,
v o l .1 0 4 ,n o .1 7 ,p p .7 0 8 0 – 7 0 8 5 ,2 0 0 7 .
[56] M. Ghisi, A. Corradin, K. Basso et al., “Modulation of
microRNA expression in human T-cell development: targeting
of NOTCH3 by miR-150,” Blood,v o l .1 1 7 ,n o .2 6 ,p p .7 0 5 3 – 7 0 6 2 ,
2011.
[57] Z.Zhang,S.Florez,A.Gutierrez-Hartmann,J.F.Martin,andB.
A. Amendt, “MicroRNAs regulate pituitary development, and
microRNA 26b specifically targets lymphoid enhancer factor 1
(Lef-1), which modulates pituitary transcription factor 1 (Pit-1)
expression,”TheJournalofBiologicalChemistry,vol.285,no .45,
pp. 34718–34728, 2010.
[ 5 8 ]H .P a i s ,F .E .N i c o l a s ,S .M .S o o n de ta l . ,“ A n a l y z i n gm R N A
expressionidentifiesSmad3asamicroRNA-140targetregulated
only at protein level,” RNA, vol. 16, no. 3, pp. 489–494, 2010.
[59] S. Liang, L. Chen, H. Huang, and D. Zhi, “The experimental
study of miRNA in pituitary adenomas,” Turkish Neurosurgery,
v o l .2 3 ,n o .6 ,p p .7 2 1 – 7 2 7 ,2 0 1 3 .
[60] J. Godoy, M. Nishimura, and N. J. G. Webster, “Gonadotropin-
releasing hormone induces miR-132 and miR-212 to regulate
cellular morphology and migration in immortalized L2 T2
pituitary gonadotrope cells,” Molecular Endocrinology,v o l .2 5 ,
n o .5 ,p p .8 1 0 – 8 2 0 ,2 0 1 1 .
[61] K. Vermeulen, D. R. Van Bockstaele, and Z. N. Berneman, “The
cell cycle: a review of regulation, deregulation and therapeutic
targets in cancer,” Cell Proliferation,v o l .3 6 ,n o .3 ,p p .1 3 1 – 1 4 9 ,
2003.
[62] C. H. McGowan and P. Russell, “Human Wee1 kinase inhibits
cell division by phosphorylating p34cdc2 exclusively on Tyr15,”
The EMBO Journal,v o l .1 2 ,n o .1 ,p p .7 5 – 8 5 ,1 9 9 3 .
[63] C. Evangelisti, M. C. Florian, I. Massimi et al., “MiR-128 up-
regulation inhibits Reelin and DCX expression and reduces
neuroblastoma cell motility and invasiveness,” FASEB Journal,
vol. 23, no. 12, pp. 4276–4287, 2009.
[64] I. Faraoni, F. R. Antonetti, J. Cardone, and E. Bonmassar, “miR-
155 gene: a typical multifunctional microRNA,” Biochimica et
Biophysica Acta: Molecular Basis of Disease,v o l .1 7 9 2 ,n o .6 ,p p .
497–505, 2009.
[65] J. Godlewski, M. O. Nowicki, A. Bronisz et al., “Targeting of
the Bmi-1 oncogene/stem cell renewal factor by MicroRNA-128
inhibitsgliomaproliferationandself-renewal,”CancerResearch,
v o l .6 8 ,n o .2 2 ,p p .9 1 2 5 – 9 1 3 0 ,2 0 0 8 .10 International Journal of Endocrinology
[66] J. A. Foekens, A. M. Sieuwerts, M. Smid et al., “Four miRNAs
associated with aggressiveness of lymph node-negative, estro-
gen receptor-positive human breast cancer,” Proceedings of the
National Academy of Sciences of the United States of America,
vol. 105, no. 35, pp. 13021–13026, 2008.
[67] M. A. Tessari, M. Gostissa, S. Altamura et al., “ Transcriptional
activationofthecyclinAgenebythearchitecturaltranscription
factor HMGA2,” Molecular and Cellular Biology,v o l .2 3 ,n o .2 4 ,
pp. 9104–9116, 2003.
[68] D. Bonci, V. Coppola, M. Musumeci et al., “The miR-15a-
miR-16-1 cluster controls prostate cancer by targeting multiple
oncogenic activities,” Nature Medicine,v o l .1 4 ,n o .1 1 ,p p .1 2 7 1 –
1277, 2008.
[69] C. Guo, J. F. Sah, L. Beard, J. K. V. Willson, S. D. Markowitz,
and K. Guda, “The noncoding RNA, miR-126, suppresses the
growth of neoplastic cells by targeting phosphatidylinositol 3-
kinase signaling and is frequently lost in colon cancers,” Genes
Chromosomes and Cancer,v o l .4 7 ,n o .1 1 ,p p .9 3 9 – 9 4 6 ,2 0 0 8 .
[70] Q. Jiang, M.-G. Feng, and Y.-Y. Mo, “Systematic validation of
predictedmicroRNAsforcyclinD1,”BMCCancer,vol.9 ,article
194, 2009.
[71] H. Sun, R. Lesche, D.-M. Li et al., “PTEN modulates cell cycle
progressionandcellsurvivalbyregulatingphosphatidylinositol
3,4,5,-trisphosphate and Akt/protein kinase B signaling path-
way,” Proceedings of the National Academy of Sciences of the
United States of America,v o l .9 6 ,n o .1 1 ,p p .6 1 9 9 – 6 2 0 4 ,1 9 9 9 .
[72] J. M. Adams and S. Cory, “The Bcl-2 apoptotic switch in cancer
development and therapy,” Oncogene,v o l .2 6 ,n o .9 ,p p .1 3 2 4 –
1337, 2007.
[73] A. Cimmino, G. A. Calin, M. Fabbri et al., “miR-15 and miR-16
induceapoptosisbytargetingBCL2,”ProceedingsoftheNational
Academy of Sciences of the United States of America,v o l .1 0 2 ,n o .
39, pp. 13944–13949, 2005.
[74] M. S´ anchez-Beato, A. S´ anchez-Aguilera, and M. A. Piris, “Cell
cycle deregulation in B-cell lymphomas,” Blood,v o l .1 0 1 ,n o .4 ,
pp. 1220–1235, 2003.
[75] S.Volinia,G.A.Calin,C.-G.Liuetal.,“AmicroRNAexpression
signature of human solid tumors defines cancer gene targets,”
Proceedings of the National Academy of Sciences of the United
States of America,v o l .1 0 3 ,n o .7 ,p p .2 2 5 7 – 2 2 6 1 ,2 0 0 6 .
[76] M. F. Corsten, R. Miranda, R. Kasmieh, A. M. Krichevsky, R.
Weissleder, and K. Shah, “MicroRNA-21 knockdown disrupts
gliomagrowthIn vivo anddisplayssynergisticcytotoxicitywith
neural precursor cell-delivered S-TRAIL in human gliomas,”
Cancer Research,v o l .6 7 ,n o .1 9 ,p p .8 9 9 4 – 9 0 0 0 ,2 0 0 7 .
[ 7 7 ]I .A .A s a n g a n i ,S .A .K .R a s h e e d ,D .A .N i k o l o v ae ta l . ,
“MicroRNA-21 (miR-21) post-transcriptionally downregulates
tumor suppressor Pdcd4 and stimulates invasion, intravasation
and metastasis in colorectal cancer,” Oncogene,v o l .2 7 ,n o .1 5 ,
p p .2 1 2 8 – 2 1 3 6 ,2 0 0 8 .
[78] H. Bai, R. Xu, Z. Cao, D. Wei, and C. Wang, “Involvement
of miR-21 in resistance to daunorubicin by regulating PTEN
expression in the leukaemia K562 cell line,” FEBS Letters,v o l .
585, no. 2, pp. 402–408, 2011.
[ 7 9 ]O .A f o n j a ,D .J u s t e ,S .D a s ,S .M a t s u h a s h i ,a n dH .H .S a m u e l s ,
“Induction of PDCD4 tumor suppressor gene expression by
RARagonists,antiestrogenandHER-2/neuantagonistinbreast
cancercells.Evidenceforaroleinapoptosis,”Oncogene,v o l .23,
n o .4 9 ,p p .8 1 3 5 – 8 1 4 5 ,2 0 0 4 .
[80] L.-P. Weng, J. L. Brown, and C. Eng, “PTEN induces apoptosis
and cell cycle arrest through phosphoinositol-3-kinase/Akt-
dependent and -independent pathways,” Human Molecular
Genetics,v o l .1 0 ,n o .3 ,p p .2 3 7 – 2 4 2 ,2 0 0 1 .
[81] D. Frezzetti, M. de Menna, P. Zoppoli et al., “Upregulation of
miR-21 by Ras in vivo and its role in tumor growth,” Oncogene,
v o l .3 0 ,n o .3 ,p p .2 7 5 – 2 8 6 ,2 0 1 1 .
[82] A.H.Stegh,O.Schickling,A.Ehretetal.,“DEDD,anoveldeath
effector domain-containing protein, targeted to the nucleolus,”
The EMBO Journal, vol. 17, no. 20, pp. 5974–5986, 1998.
[ 8 3 ] J .Y u ,D .G .R y a n ,S .G e t s i o s ,M .O l i v e i r a - F e r n a n d e s ,A .F a t i m a ,
and R. M. Lavker, “MicroRNA-184 antagonizes microRNA-
205 to maintain SHIP2 levels in epithelia,” Proceedings of the
National Academy of Sciences of the United States of America,
vol. 105, no. 49, pp. 19300–19305, 2008.
[84] A. M. Cheng, M. W. Byrom, J. Shelton, and L. P. Ford,
“Antisense inhibition of human miRNAs and indications for an
involvement of miRNA in cell growth and apoptosis,” Nucleic
Acids Research,v o l .3 3 ,n o .4 ,p p .1 2 9 0 – 1 2 9 7 ,2 0 0 5 .
[85] C.-H.Chen,W.-W.Xiao,X.-B.Jiangetal.,“Anovelmarinedrug,
sz-685c, induces apoptosis of mmq pituitary tumor cells by
downregulating mir-200c,” Current Medicinal Chemistry,v o l .
20, no. 16, pp. 2145–2154, 2013.
[86] E. Kulig, L. Jin, X. Qian et al., “Apoptosis in nontumorous and
neoplastic human pituitaries: expression of the Bcl-2 family of
proteins,” The American Journal of Pathology,v o l .1 5 4 ,n o .3 ,p p .
767–774, 1999.
[87] H. Kasai, J. T. Allen, R. M. Mason, T. Kamimura, and Z. Zhang,
“TGF-𝗽1induceshumanalveolarepithelialtomesenchymalcell
transition (EMT),” Respiratory Research,v o l .6 ,a r t i c l e5 6 ,2 0 0 5 .
[88] J. Yu, F. Xie, X. Bao, W. Chen, and Q. Xu, “miR-300 inhibits
epithelial to mesenchymal transition and metastasis by target-
ingTwistinhumanepithelial cancer,” Molecular Cancer,v o l .13,
article 121, 2014.
[ 8 9 ]G .F a b j a n i ,D .T o n g ,A .W o l fe ta l . ,“ H M G A 2i sa s s o c i a t e d
with invasiveness but not a suitable marker for the detection of
circulating tumor cells in breast cancer,” Oncology Reports,v o l .
14, no. 3, pp. 737–741, 2005.
[ 9 0 ] K .M o t o y a m a ,H .I n o u e ,Y .N a k a m u r a ,H .U e t a k e ,K .S u g i h a r a ,
and M. Mori, “Clinical significance of high mobility group A2
in human gastric cancer and its relationship to let-7 microRNA
family,” Clinical Cancer Research,v o l .1 4 ,n o .8 ,p p .2 3 3 4 – 2 3 4 0 ,
2008.
[91] J. Miyazawa, A. Mitoro, S. Kawashiri, K. K. Chada, and K.
Imai, “Expression of mesenchyme-specific gene HMGA2 in
squamous cell carcinomas of the oral cavity,” Cancer Research,
vol. 64, no. 6, pp. 2024–2029, 2004.
[92] Z. R. Qian, T. Sano, K. Yoshimoto et al., “Tumor-specific
downregulation and methylation of the CDH13 (H-cadherin)
and CDH1 (E-cadherin) genes correlate with aggressiveness of
human pituitary adenomas,” Modern Pathology,v o l .2 0 ,n o .1 2 ,
pp. 1269–1277, 2007.
[93] F. Salehi, K. Kovacs, B. W. Scheithauer, R. V. Lloyd, and M.
Cusimano, “Pituitary tumor-transforming gene in endocrine
and other neoplasms: a review and update,” Endocrine-Related
Cancer,v o l .1 5 ,n o .3 ,p p .7 2 1 – 7 4 3 ,2 0 0 8 .
[94] A. S. Bates, W. E. Farrell, E. J. Bicknell et al., “Allelic deletion
in pituitary adenomas reflects aggressive biological activity and
has potential value as a prognostic marker,” Journal of Clinical
Endocrinology and Metabolism,v o l .8 2 ,n o .3 ,p p .8 1 8 – 8 2 4 ,1 9 9 7 .International Journal of Endocrinology 11
[95] X.Fan,A.Paetau,Y.Aaltoetal.,“Gainofchromosome3andloss
of 13q are frequent alterations in pituitary adenomas,” Cancer
Genetics and Cytogenetics,v o l .1 2 8 ,n o .2 ,p p .9 7 – 1 0 3 ,2 0 0 1 .
[96] G. Stilling, Z. Sun, S. Zhang et al., “MicroRNA expres-
sion in ACTH-producing pituitary tumors: up-regulation of
microRNA-122 and -493 in pituitary carcinomas,” Endocrine,
v o l .3 8 ,n o .1 ,p p .6 7 – 7 5 ,2 0 1 0 .
[ 9 7 ]B . - H .G u o ,Y .F e n g ,R .Z h a n ge ta l . ,“ B m i - 1p r o m o t e si n v a s i o n
and metastasis, and its elevated expression is correlated with
an advanced stage of breast cancer,” Molecular Cancer,v o l .1 0 ,
article 10, 2011.
[98] M. Tamura, J. Gu, T. Takino, and K. M. Yamada, “Tumor
suppressor PTEN inhibition of cell invasion, migration, and
growth: differential involvement of focal adhesion kinase and
p130(Cas),” Cancer Research,v o l .5 9 ,n o .2 ,p p .4 4 2 – 4 4 9 ,1 9 9 9 .
[99] J. J. Orrego and A. L. Barkan, “Pituitary disorders: drug
treatment options,” Drugs,v o l .5 9 ,n o .1 ,p p .9 3 – 1 0 6 ,2 0 0 0 .
[100] U. Pl¨ ockinger, S. Albrecht, C. Mawrin et al., “Selective loss of
somatostatin receptor 2 in octreotide-resistant growth hor-
mone-secreting adenomas,” The Journal of Clinical Endocrinol-
ogy & Metabolism,v o l .9 3 ,n o .4 ,p p .1 2 0 3 – 1 2 1 0 ,2 0 0 8 .
[101] M. Furuta, K.-I. Kozaki, S. Tanaka, S. Arii, I. Imoto, and J.
Inazawa, “miR-124 and miR-203 are epigenetically silenced
tumor-suppressive microRNAs in hepatocellular carcinoma,”
Carcinogenesis,v o l .3 1 ,n o .5 ,p p .7 6 6 – 7 7 6 ,2 0 0 9 .